Basit öğe kaydını göster

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia

dc.contributor.authorShetty, J. K.
dc.contributor.authorKattamis, A.
dc.contributor.authorVlachaki, E.
dc.contributor.authorOriga, R.
dc.contributor.authorAydinok, Y.
dc.contributor.authorBejaoui, M.
dc.contributor.authorHo, P. J.
dc.contributor.authorChew, L. -P.
dc.contributor.authorBee, P. -C.
dc.contributor.authorLim, S. -M.
dc.contributor.authorLu, M. -Y.
dc.contributor.authorTantiworawit, A.
dc.contributor.authorGaneva, P.
dc.contributor.authorGercheva, L.
dc.contributor.authorShah, F.
dc.contributor.authorNeufeld, E. J.
dc.contributor.authorThompson, A.
dc.contributor.authorLaadem, A.
dc.contributor.authorLal, A.
dc.contributor.authorZou, J.
dc.contributor.authorZhang, J.
dc.contributor.authorMiteva, D.
dc.contributor.authorZinger, T.
dc.contributor.authorLinde, P. G.
dc.contributor.authorSherman, M. L.
dc.contributor.authorHermine, O.
dc.contributor.authorPorter, J.
dc.contributor.authorPiga, A.
dc.contributor.authorCappellini, M. D.
dc.contributor.authorViprakasit, V.
dc.contributor.authorTaher, A. T.
dc.contributor.authorGeorgiev, P.
dc.contributor.authorKuo, K. H. M.
dc.contributor.authorCoates, T.
dc.contributor.authorVoskaridou, E.
dc.contributor.authorLiew, H. -K.
dc.contributor.authorPazgal-Kobrowski, I.
dc.contributor.authorForni, G. L.
dc.contributor.authorPerrotta, S.
dc.contributor.authorKhelif, A.
dc.date.accessioned2021-12-10T12:39:49Z
dc.date.available2021-12-10T12:39:49Z
dc.date.issued2020
dc.identifier.citationCappellini M. D. , Viprakasit V., Taher A. T. , Georgiev P., Kuo K. H. M. , Coates T., Voskaridou E., Liew H. -. , Pazgal-Kobrowski I., Forni G. L. , et al., "A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia", NEW ENGLAND JOURNAL OF MEDICINE, cilt.382, sa.13, ss.1219-1231, 2020
dc.identifier.issn0028-4793
dc.identifier.otherav_cd6fcb57-872c-4a0d-b811-2c7ce51a11c5
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/174364
dc.identifier.urihttps://doi.org/10.1056/nejmoa1910182
dc.description.abstractBackground Patients with transfusion-dependent beta-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor beta superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients.
dc.language.isoeng
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectFundamentals and Skills
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectFamily Practice
dc.subjectTemel Tıp Bilimleri
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleA Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia
dc.typeMakale
dc.relation.journalNEW ENGLAND JOURNAL OF MEDICINE
dc.contributor.departmentUniversity Of Milan , ,
dc.identifier.volume382
dc.identifier.issue13
dc.identifier.startpage1219
dc.identifier.endpage1231
dc.contributor.firstauthorID2741837


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster